Premium
The effect of lovastatin on very low‐density lipoprotein apolipoprotein B production by the liver in familial combined hyperlipidaemia
Author(s) -
Cortner J. A.,
Bennett M. J.,
Le N. A.,
Coates P. M.
Publication year - 1993
Publication title -
journal of inherited metabolic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 102
eISSN - 1573-2665
pISSN - 0141-8955
DOI - 10.1007/bf00711326
Subject(s) - lovastatin , apolipoprotein b , medicine , endocrinology , lipoprotein , cholesterol , biology , familial hypercholesterolemia
Summary Overproduction of very low‐density lipoprotein apolipoprotein B by the liver is a metabolic marker for familial combined hyperlipidaemia, a common inherited disorder of lipoprotein metabolism. Four subjects with familial combined hyperlipidaemia had rates of apolipoprotein B production which were 2–7 times normal, using a protocol in which [ 15 N]nglycine was used to label newly synthesized hepatic proteins. Following 4–6 months of therapy with lovastatin, very low‐density lipoprotein apolipoprotein B production in all four subjects had returned to the normal range. This demonstrates that lovastatin, an inhibitor of cholesterol biosynthesis, acts also to reduce the apparent production rate of apolipoprotein B by the liver.